DARIUS ANDERSON TO JOIN STEMEDICA BOARD OF DIRECTORS

by stemedica admin | Mar 30, 2022 | Company Initiatives

Respected and seasoned business leader, investor and political strategist offers multiple talents to stem cell technologies company SAN DIEGO, March 30, 2022 /PRNewswire/ — Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based...

Mesenchymal stem cells in the treatment of severe COVID-19

by stemedica admin | Sep 20, 2021 | Publications

Santosh Kesari1,2*, Gregory C. Kasper3*, Lev Verkh4 , Terese C. Hammond5 , Marla L. Matal3 , Jay W. Hammerling3 , Nikolai Tankovich4 , Adrianus P. Lim3 , Kevin H. Zhao3 , Tifany Juarez1 , Roberta E. Redfern3 , Jaya M. Gill6 , Natsuko Nomura1 , Audrey Hiemer1 , Annie...

StemProtein Awarded U.S. Patent for Biodegradable Microneedle Device

by stemedica admin | Aug 22, 2021 | Company Initiatives

Dissolvable Needles Allow Dermis Delivery of Proteins and Large Molecules SAN DIEGO — August 23, 2021 — StemProtein, LLC (a subsidiary of Stemedica Cell Technologies, Inc.) a leading manufacturer of physiologically balanced growth factors, exosomes, and...

Stemedica Opens Enrollment in Phase II Clinical Trial for COVID-19 A Phase II Study in Patients with Moderate to Severe ARDS Using GMP, Allogeneic, Bone Marrow-Derived, Ischemic-Tolerant Mesenchymal Stem Cells

by stemedica admin | Aug 5, 2021 | Clinical Trials

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ — Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announces enrollment of patients for its...

Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19

by stemedica admin | May 23, 2021 | Company Initiatives

SAN DIEGO, California, May 24, 2021 – Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announced today that it has signed a Licensing Agreement with Pulthera, LLC for the...